Consolidative Stem Cell Transplant May Improve Outcomes Among Patients With PTCL
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Hematopoietic Stem Cell Transplantation
Allo-HSCT May Be Promising Strategy in Relapsed or Refractory PMBCL
Researchers sought to determine whether allo-HSCT would be effective for inducing durable remission among patients with relapsed or refractory PMBCL.
Improved Outcomes Seen With Combined Cyclophosphamide and Antithymocyte Globulin in PBSCT
Researchers sought to determine if the combination of PTC-gamma and low-dose antithymocyte globulin could improve efficacy in patients who underwent haplo-PBSCT.
Unrelated Cord Blood May Be Effective Alternative to HLA-Matched Sibling Donor in Adult B-ALL
Researchers sought to determine whether use of UBC for allo-HSCT would have comparable efficacy with a HLA-matched sibling donor in patients with B-ALL.
Hematopoietic Stem Cell Transplantation Shows Positive Efficacy for Inborn Errors of Immunity
Researchers sought to identify outcomes for adolescents and adults with inborn errors of immunity treated with HSCT.
Bendamustine Plus Rituximab Appears Effective in Treating First-Line, Transplant-Eligible Mantle Cell Lymphoma
Researchers sought to determine whether first-line rituximab plus bendamustine followed by ASCT would be an effective treatment option for MCL.
MRD Persistence Is Associated With Increasing Risk for Relapse of Mantle Cell Lymphoma
Researchers sought to determine whether MRD may predict relapse risk in patients with MCL.
Risk of TA-TMA Elevated in Children With Sickle Cell Disease
Researchers sought to determine the risk of transplant-associated thrombotic microangiopathy in children with SCD.
BuCy Noninferior to TBI-Cy as Conditioning Regimen for Patients With B-ALL Undergoing Allo-HSCT
Researchers sought to determine whether a BuCy conditioning regimen would be effective in patients with B-ALL undergoing HLA-matched allo-HSCT.
2-Year Nonrecurrence Linked With Improved Long-Term Survival With Haplo-SCT
Researchers sought to determine whether there could be a link between haplo-SCT and survival in patients with hematologic malignancies who remain disease free for 2 years.
- Loading...
Loading...
Loading... 
Loading...